Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TNX-103

Phase 3Small molecule

TTenax Therapeutics, Inc.

1

Indications

3

Total Trials

3

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary Hypertension Associated With HfpefEnrolling by invitation

Pulmonary Hypertension Associated With HfpefPhase 3

Enrolling by invitation

Timeline

Expected Milestones

Q4 2028

Phase 3Active, not recruiting

Pulmonary Hypertension

NCT05983250

Q2 2029

Phase 3Recruiting

Pulmonary Hypertension Associated With Hfpef

NCT07288398

Clinical

Trials by Indication[1]

Pulmonary Hypertension Associated With HFpEF2 trials

A Multicenter, Open-Label, Long-Term Extension Study for Oral Levosimendan (TNX-103)

Enrolling by invitation·TTenax Therapeutics, Inc.·Phase 3·NCT07436689·800 enrolled

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction

Recruiting·TTenax Therapeutics, Inc.·Phase 3·NCT07288398·540 enrolled

Pulmonary Hypertension1 trial

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

Active, not recruiting·TTenax Therapeutics, Inc.·Phase 3·NCT05983250·230 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for TNX-103. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TNX-103 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TNX-103. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tenax Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTenax Therapeutics, Inc.

Related News